Clinical implications of the evidence from IV iron trials in HF
10' education - Nov. 15, 2023 - Stefan Anker, MD, PhD, Robert Mentz, MD, and Piotr Ponikowski, MD, PhD2023 ESC Guideline Updates: Where are we with iron deficiency?
10' education - Oct. 23, 2023 - Giuseppe M.C. Rosano, MD, PhD, Marco Metra, MD, and Gianluigi Savarese, MD, PhDA practical look at cardiorenal protection for CKD in T2D: Applying recent data
15' education - Oct. 19, 2023 - Carolyn Lam, MD, PhD, Maria Luiza Caramori, MD, PhD, Ana Maria Cebrián-Cuenca, MD, PhD, and Pam Taub, MDWhat is the totality of evidence for IV iron treatment outcomes in patients with HF?
15' education - Sep. 28, 2023 - Giuseppe M.C. Rosano, MD, PhD, Antoni Bayés-Genís, MD, PhD, and Ovidiu Chioncel, MD, PhDPolypharmacy: Adding nonsteroidal MRAs, when and how
10' education - July 24, 2023 - Tessa Laubscher, MD, George L. Bakris, MD, and Mikhail Kosiborod, MDHyperkalemia: Is it still a challenge in 2023?
10' education - July 11, 2023 - Ileana L. Piña, MD, Javed Butler, MD, and Patrick Rossignol, MD, PhDInitiation of SGLT2i in CKD: how, when and who?
10' education - June 27, 2023 - David Cherney, MD, PhD, Roberto Pecoits-Filho, MD, PhD, and Magdalena Madero, MDMaintaining GDMT while lowering potassium in heart failure
10' education - Mar. 27, 2023 - Javed Butler, MD, Ileana L. Piña, MD, and Patrick Rossignol, MD, PhDRevascularization in high-risk PCI patients
10' education - Feb. 28, 2023 - Navin Kapur, MD, Adam DeVore, MD, Lauren Barron, MD,Treating iron deficiency in patients with HFrEF: A review of the recent data for IV iron replacement therapy
10' education - Jan. 5, 2023 - Prof. Javed Butler, MD, Prof. Stefan Anker, MD, PhD, Piotr Ponikowski, MD, PhD, and Robert J. Mentz, MDApplying GDMT for iron deficiency in heart failure
10' education - Nov. 17, 2022 - Prof. Piotr Ponikowski, MD, PhD, Adrian F. Hernandez, MD, Prof. Andrew Sindone, MDThe role of potassium binders in optimal HF management: Discussing the DIAMOND study
10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD, Prof. Stefan D. Anker, MD, PhD, Prof. Javed Butler, MD, Prof. Bertram Pitt, MDAddressing late-breaking data on triglycerides, fibrates and omega-3FAs
15' education - Nov. 16, 2022 - Prof. Peter Libby, MD, Prof. Gabriel Steg, MD, Prof. Kausik Ray, MDA new option for cardiorenal protection for patients with CKD and T2DM
10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhDDiscussion - Clinical dilemmas in heart failure: Weighing the balance of RAASi and hyperkalaemia
10' education - July 20, 2022 - Prof. Andrew Coats, MD, Clara Bonanad Lozano, MD, PhD, and Aaron Wong, MDDiscussion - Rethinking the role of nephrologists in prevention of CKD - The opportunity of early risk identification
10' education - July 6, 2022 - Prof. Christoph Wanner, MD, Rikke Borg, MD, PhD, and prof. Kamlesh Khunti, MD, PhDDiscussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA
10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MDDiscussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl
10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhDPCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c
3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, PhiladelphiaWhy cardiologists should be more interested in PAH
3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CMEEmerging approaches to dyslipidemia management beyond LDL-c
3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USAStatin-associated muscle symptoms: real or nocebo effect?
3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. Paul Thompson, Hartford, CT, USAThe ORBITA trial: is PCI beneficial in stable angina patients?
3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. William Boden, Boston, MA, USAMutated bone marrow stem cells may link aging, cancer and atherosclerosis
3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - Prof. Peter Libby, Boston, MA, USAResults of ODYSSEY OUTCOMES and FOURIER trials complement each other
3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USAPharmacist intervention in black barbershop beats usual care at lowering BP
3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USANo evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial
3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USAA threefold role of cardiologists as advocates for better cardiology care
3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, VS - Mary Norine Walsh, MD - Indianapolis, IN, USAGiving NOAC treatment at myocardial injury after non-cardiac surgery lowers major vascular complications
3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - P.J. Devereaux - Hamilton, ON, CanadaTotal mortality, but not sudden cardiac death, lower by wearable cardioverter-defibrillator in the immediate post-MI period with low EF
3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL. USA - Jeffrey Olgin (San Francisco, CA, USAResults ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients
3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USALipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies
10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USANew ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target
3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USAPCSK9 inhibition across a wide spectrum of patients: One size fits all?
10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CMEUnderstanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality
10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CMEHow low to go with blood pressure: J-curve or not?
3' education - Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)HFpEF in older adults: TTR amyloid, under diagnosed and treatable?
3' education - Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)Investigational epigenetic therapy lowers incidence of MACE in phase 2b study
3' education - Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, CanadaNo clinical benefit of potent P2Y12 inhibitor over clopidogrel in peripheral artery disease
3' education - Jan. 4, 2017 - AHA 2016, New Orleans, LA, USA - Prof. Freek Verheugt, Amsterdam, The NetherlandsWould lower than the current ApoB targets be more useful for clinical decision-making?
10' education - Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).Emerging therapies and treatment strategies in pulmonary arterial hypertension
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul R. Forfia, MD - Philadelphia, PA, USAOral anticoagulation in daily clinical practice in varous patient populations
10' education - Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)Inflammation as potential target for therapy to target residual risk post ACS
10' education - Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USAA clinical perspective on PCSK9 inhibition: What do we know an what can we expect?
10' education - Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USASurviving elevated Lp(a): a patient story from diagnosis to treatment
10' education - May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EASA patient with elevated Lp(a): What is current clinical practice to manage this condition?
10' education - May 27, 2016 - Innsbruck, Germany - Prof. Klaus G. Parhofer, MD - University of Munich, Germany - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EASThe future perspectives for care for patients with high Lp(a)
10' education - May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EASOverview of SGLT-2 inhibitors in T2DM management: current position & future promise
10' education - Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, RomeUnderstanding BET inhibition as a novel pathway for cardiovascular risk modulation
10' education - Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016Novel small molecule that inhibits PAI-1 in development to slow vascular aging
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Douglas E. Vaughan, MD - Chicago, IL, USATwo additions to the therapeutic armory to treat HFrEF
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Boston, MA, USAInadequate anticoagulant treatment for stroke prevention in atrial fibrillation
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Christian T. Ruff, MD - Boston, MA, USAHow to treat residual inflammatory risk?
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USAEvolving hypotheses on the mechanisms underlying ACS
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USANew therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USAElucidating the role of gut microbes in CVD may provide future therapeutic strategies
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Stanley L. Hazen, MD, PhD - Cleveland, OH, USASteps forward in lipid-lowering therapy
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USAManaging cardiorenal syndrome in the context of heart failure
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter A. McCullough, MD - Dallas, TX, USABP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk
10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
